Week In Review: Apollomics Merges With SPAC To Support Candidates Targeting Difficult-To-Treat Cancers

Apollomics, Inc., a US-China biopharma, merged with a SPAC to list on the Nasdaq exchange. At the merger price of $10/share, Apollomics had a market cap of about $900 million, but the shares have climbed 121% higher in trading.